基于多模态磁共振影像组学构建低级别胶质瘤MGMT启动子甲基化预测模型研究

低级别胶质瘤（LGG）生物学行为具有显著异质性，生存期差异大。最新研究表明，替莫唑胺可改善O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化LGG患者预后。准确评估MGMT启动子甲基化状态是预测LGG替莫唑胺敏感性的关键因素，具有重要科学意义。目前，主要由测序评估MGMT启动子甲基化，其有创、昂贵且不能全面体现LGG异质性。应用多模态磁共振（MRI）影像组学提取海量肉眼无法识别的影像特征，全面定量评估LGG生物学异质性，可为MGMT甲基化状态评估提供精准信息。本课题组前期研究结果表明，基于MRI常规序列影像组学可以提高胶质瘤MGMT甲基化的诊断效能，但无法针对LGG精准预测。因此，本研究拟应用多模态MRI影像组学方法，构建低级别胶质瘤MGMT启动子甲基化的早期诊疗预测模型，实现MGMT启动子甲基化状态的术前无创定量评估，为LGG的精准诊疗提供依据，对延长患者生存期有重要价值。

Low grade glioma (LGG) display significant variability in biological behavior and survival time. Recent studies have found a prognostic effect of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in patients with LGG treated with temozolomide-based chemoradiotherapy. Accurate assessment of methylation status of MGMT is essential to evaluate the sensitivity of LGG to temozolomide, which has important scientific significance. At present, the methylation status of MGMT promoter is mainly evaluated by gene sequencing, which is invasive, expensive and can not fully reflect the heterogeneity of LGG. The application of multimodal magnetic resonance imaging(MRI) radiomics to extract a large number of unrecognizable image features and quantitatively evaluate the biological heterogeneity of LGG can provide accurate information for the assessment of methylation status of MGMT. Previous research results of our group show that radiomics based on conventional MRI sequence can improve the diagnostic efficiency of MGMT methylation in glioma, but it can not accurately predict LGG. Therefore, this study intends to construct an early diagnosis and treatment prediction model for LGG MGMT promoter methylation by using multi-modal MRI radiomics, to realize the non-invasive quantitative assessment of methylation status of MGMT promoter, and to provide an accurate diagnosis and treatment of LGG，which is of great value for prolonging the survival time of patients.